Shares of Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) shot up 5.3% on Thursday . The stock traded as high as $3.13 and last traded at $2.98, 112,400 shares changed hands during trading. A decline of 69% from the average session volume of 363,338 shares. The stock had previously closed at $2.83.
Several brokerages recently weighed in on OSMT. Royal Bank of Canada restated a “buy” rating and set a $10.00 price objective on shares of Osmotica Pharmaceuticals in a research report on Wednesday, March 25th. ValuEngine downgraded Osmotica Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday. SVB Leerink initiated coverage on Osmotica Pharmaceuticals in a research report on Friday, March 6th. They set an “outperform” rating and a $10.00 price objective for the company. BidaskClub cut Osmotica Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 4th. Finally, SunTrust Banks initiated coverage on Osmotica Pharmaceuticals in a report on Wednesday, March 18th. They issued a “buy” rating and a $8.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Osmotica Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $8.36.
The company has a market cap of $163.84 million, a price-to-earnings ratio of -0.58 and a beta of 4.16. The firm has a 50 day moving average price of $4.93 and a two-hundred day moving average price of $5.26. The company has a quick ratio of 1.99, a current ratio of 2.27 and a debt-to-equity ratio of 2.36.
In other Osmotica Pharmaceuticals news, Director Sriram Venkataraman bought 1,250,000 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The shares were bought at an average price of $5.00 per share, for a total transaction of $6,250,000.00. Following the transaction, the director now directly owns 22,485,297 shares in the company, valued at $112,426,485. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 4.70% of the stock is owned by corporate insiders.
A number of large investors have recently made changes to their positions in OSMT. State of Tennessee Treasury Department bought a new position in Osmotica Pharmaceuticals in the fourth quarter worth approximately $26,000. Tower Research Capital LLC TRC boosted its holdings in Osmotica Pharmaceuticals by 1,412.6% in the third quarter. Tower Research Capital LLC TRC now owns 9,454 shares of the company’s stock worth $36,000 after acquiring an additional 8,829 shares in the last quarter. Citigroup Inc. boosted its holdings in Osmotica Pharmaceuticals by 330.6% in the fourth quarter. Citigroup Inc. now owns 5,598 shares of the company’s stock worth $39,000 after acquiring an additional 4,298 shares in the last quarter. Barclays PLC boosted its holdings in Osmotica Pharmaceuticals by 103.0% in the fourth quarter. Barclays PLC now owns 8,226 shares of the company’s stock worth $57,000 after acquiring an additional 4,174 shares in the last quarter. Finally, First Trust Advisors LP bought a new position in Osmotica Pharmaceuticals in the third quarter worth approximately $69,000. Institutional investors and hedge funds own 6.81% of the company’s stock.
Osmotica Pharmaceuticals Company Profile (NASDAQ:OSMT)
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.
Featured Story: How is diluted EPS different from basic EPS?
Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.